Connect to share and comment

Pfizer lung cancer drug beats chemo for previously untreated patients

(Reuters) - Pfizer Inc's Xalkori delayed progression of lung cancer longer than chemotherapy in patients who had never previously been treated for the disease, according to results of a late-stage study released on Tuesday. The medicine, which received U.S. approval in 2011 for lung cancer patients who have a specific gene mutation, had shown in a previous Phase III trial that it significantly delayed disease progression among those who have already undergone chemotherapy for non-small-cell lung cancer, the most common form of the illness.

Pfizer trading halted briefly over news court invalidated patent for arthritis drug Celebrex

TRENTON, N.J. - A federal court on Wednesday invalidated the key patent for one of Pfizer's most lucrative medicines, potentially opening the door for cheaper generic versions 18 months sooner than expected and cutting into the drugmaker's profit.

Pfizer breast cancer drug succeeds in mid-stage trial

By Ransdell Pierson (Reuters) - Pfizer Inc's experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study's primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease. Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company's most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved.

Pfizer says lung cancer drug fails two late-stage studies

(Reuters) - Pfizer Inc said its experimental lung cancer drug failed to meet its goals in two late-stage studies in patients with advanced non-small cell lung cancer. The company said the drug, dacomitinib, did not show improved survival without the cancer worsening in patients when compared with another non-small cell lung cancer drug. The patients were previously treated with chemotherapy. Pfizer said the drug did not prolong overall survival compared with a placebo in a second study.

Pfizer will allow Teva to sell generic Viagra

(Reuters) - Pfizer Inc on Tuesday said it would allow Teva Pharmaceutical Industries to sell generic forms of its Viagra anti-impotence treatment in the United States beginning in late 2017, in a settlement of longstanding patent litigation between the two drugmakers. Pfizer's U.S. patent on Viagra lapses in 2020, including a six-month extension granted for having tested the medicine in young patients. That means Israeli drugmaker Teva, under the arrangement, could launch its generic version several years before other generic drugmakers.

Pfizer, Teva reach deal to allow launch of generic Viagra by 2017

Pfizer Inc. has reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017. Pfizer said Tuesday that Teva will pay an undisclosed royalty for a license to produce a generic version of Viagra, one of New York-based Pfizer's bestselling drugs. Viagra generated about $1.14 billion in U.S. sales last year and more than $2 billion worldwide.

U.S. high court leaves intact $142 million verdict against Pfizer

By Lawrence Hurley WASHINGTON (Reuters) - The U.S. Supreme Court on Monday left intact a $142 million jury verdict against Pfizer Inc over the company's marketing of the epilepsy drug Neurontin. In 2010, a jury in Massachusetts found that due to Pfizer's marketing of the drug for off-label uses, Kaiser Foundation Health Plan Inc, one of the nation's largest health maintenance organizations, and affiliates were damaged because they paid for prescriptions relating to conditions Neurontin did not effectively treat.

Pfizer to expand clinical data access to researchers, patients

By Bill Berkrot NEW YORK (Reuters) - Global drugmaker Pfizer Inc will broaden access to information from its scores of clinical trials to independent researchers and to patients who take part in the studies, the company said on Wednesday. Pfizer, the largest U.S. pharmaceutical company, said it hoped the enhanced access to its data will help spur further scientific and medical research as well as encourage more patients to get involved in clinical trials.

Pfizer third-quarter profit beats estimates, oncology drugs shine

By Ransdell Pierson (Reuters) - Pfizer Inc reported better-than-expected third-quarter earnings on Tuesday, helped by cuts in costs and growing sales of cancer medicines approved over the past two years. The largest U.S. drugmaker, whose shares rose 1.7 percent, earned $2.59 billion, or 39 cents per share. That compared with $3.21 billion, or 43 cents per share, in last year's quarter.

Drugmaker Pfizer posts 19 pct drop in 3Q profit due to generic competition, higher costs

Pfizer Inc.'s third-quarter profit dropped 19 per cent as competition from generic drugs continued to cut sales, while lower operating expenses failed to offset higher taxes and charges. Like many other drugmakers, Pfizer is suffering as cheaper generic versions erode sales of older drugs, no longer protected by patents, that once brought in billions annually. That's costing the company $3 billion to $4 billion a year. Those are led by cholesterol fighter Lipitor, which lost patent protection in November 2011 after nearly a decade as the world's top-selling drug.
Syndicate content